PO112

Abstract

Purpose A meta-analysis aimed to systematically evaluate the safety and efficiency of iodine-125 (125I) irradiation stent placement for patients with malignant biliary obstruction (MBO) Methods Embase, Medline, PubMed, Cochrane library, and OVID were systematically searched from the earliest to November 2021. The primary endpoints were stent patency and overall survival. The secondary endpoints were total bilirubin (TB) and alanine aminotransferase (ALT) level and complications. Two independent researchers strictly screened the documents, extracted the valuable data, and evaluated the quality of documents. Meta-analysis was performed using Stata 12.0 and RevMan 5.4 software. Results 950 patients were included in nine studies, 415 of them received 125I seed implantation and 535 were in the mental stents group. Meta analysis showed that the stent patency rate in the experimental group improved in 3 months (OR=5.19, 95%CI=2.74-9.8,P<0.01), and that in MBO patients also significantly increased in 6 months (OR=4.46, 95%CI=2.87-6.93, P<0.01). Meanwhile, the postoperative 6-month survival rate was significantly improved (OR=1.63, 95%CI=1.13-2.35, P=0.009).It also reduced patient's mortality risk (HR=0.67, 95%CI=0.5-0.86, P=0.002). Subgroup analysis found that different doses may lead to different patency rates. However, the postoperative 12-month survival rate was not improved. (OR=1.42, 95%CI=0.27-2.6, P=0.25). There was no significant difference in the occurrence of adverse events between the two groups (OR=1.24, 95%CI=0.69-2.21. P=0.47). Conclusions For patients with unresectable malignant biliary obstruction (MBO), placement of an irradiation stent has been demonstrated to offer longer patency and survival compared with the control group. Our aim was to further assess the efficacy of irradiation stents. A meta-analysis aimed to systematically evaluate the safety and efficiency of iodine-125 (125I) irradiation stent placement for patients with malignant biliary obstruction (MBO) Embase, Medline, PubMed, Cochrane library, and OVID were systematically searched from the earliest to November 2021. The primary endpoints were stent patency and overall survival. The secondary endpoints were total bilirubin (TB) and alanine aminotransferase (ALT) level and complications. Two independent researchers strictly screened the documents, extracted the valuable data, and evaluated the quality of documents. Meta-analysis was performed using Stata 12.0 and RevMan 5.4 software. 950 patients were included in nine studies, 415 of them received 125I seed implantation and 535 were in the mental stents group. Meta analysis showed that the stent patency rate in the experimental group improved in 3 months (OR=5.19, 95%CI=2.74-9.8,P<0.01), and that in MBO patients also significantly increased in 6 months (OR=4.46, 95%CI=2.87-6.93, P<0.01). Meanwhile, the postoperative 6-month survival rate was significantly improved (OR=1.63, 95%CI=1.13-2.35, P=0.009).It also reduced patient's mortality risk (HR=0.67, 95%CI=0.5-0.86, P=0.002). Subgroup analysis found that different doses may lead to different patency rates. However, the postoperative 12-month survival rate was not improved. (OR=1.42, 95%CI=0.27-2.6, P=0.25). There was no significant difference in the occurrence of adverse events between the two groups (OR=1.24, 95%CI=0.69-2.21. P=0.47). For patients with unresectable malignant biliary obstruction (MBO), placement of an irradiation stent has been demonstrated to offer longer patency and survival compared with the control group. Our aim was to further assess the efficacy of irradiation stents.